Macquarie Group Ltd. Takes Position in Lantheus Holdings Inc (LNTH)

Macquarie Group Ltd. acquired a new position in shares of Lantheus Holdings Inc (NASDAQ:LNTH) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 52,316 shares of the medical equipment provider’s stock, valued at approximately $931,000. Macquarie Group Ltd. owned 0.14% of Lantheus at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Ameriprise Financial Inc. boosted its holdings in shares of Lantheus by 10.1% during the 3rd quarter. Ameriprise Financial Inc. now owns 461,212 shares of the medical equipment provider’s stock worth $8,209,000 after buying an additional 42,170 shares during the period. 361 Capital LLC bought a new stake in shares of Lantheus during the 3rd quarter worth $1,933,000. Cypress Capital Management LLC WY bought a new stake in shares of Lantheus during the 3rd quarter worth $382,000. Cambridge Investment Research Advisors Inc. bought a new stake in shares of Lantheus during the 3rd quarter worth $517,000. Finally, Russell Investments Group Ltd. boosted its holdings in shares of Lantheus by 14.6% during the 3rd quarter. Russell Investments Group Ltd. now owns 321,681 shares of the medical equipment provider’s stock worth $5,726,000 after buying an additional 41,028 shares during the period. 91.95% of the stock is owned by institutional investors and hedge funds.

In other news, Director Derace L. Schaffer sold 15,000 shares of the stock in a transaction on Wednesday, September 13th. The shares were sold at an average price of $17.50, for a total value of $262,500.00. Following the completion of the transaction, the director now owns 48,730 shares in the company, valued at approximately $852,775. The sale was disclosed in a filing with the SEC, which is available at this link. Also, SVP Timothy G. Healey sold 11,314 shares of the stock in a transaction on Friday, November 17th. The shares were sold at an average price of $21.51, for a total transaction of $243,364.14. The disclosure for this sale can be found here. Over the last three months, insiders sold 44,986 shares of company stock valued at $887,988. Insiders own 2.30% of the company’s stock.

Several research firms recently issued reports on LNTH. BidaskClub downgraded shares of Lantheus from a “strong-buy” rating to a “buy” rating in a report on Tuesday, December 5th. ValuEngine downgraded shares of Lantheus from a “buy” rating to a “hold” rating in a report on Friday, December 1st. Zacks Investment Research downgraded shares of Lantheus from a “strong-buy” rating to a “hold” rating in a report on Thursday, November 9th. Jefferies Group increased their price target on shares of Lantheus from $22.00 to $27.00 and gave the company a “buy” rating in a report on Friday, November 3rd. Finally, Credit Suisse Group increased their price target on shares of Lantheus from $19.00 to $23.00 and gave the company a “neutral” rating in a report on Friday, November 3rd. Three research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $24.50.

Shares of Lantheus Holdings Inc (LNTH) opened at $20.85 on Monday. The company has a quick ratio of 2.46, a current ratio of 2.96 and a debt-to-equity ratio of -3.41. Lantheus Holdings Inc has a 1-year low of $7.95 and a 1-year high of $24.10. The firm has a market cap of $782.00, a price-to-earnings ratio of 18.62, a price-to-earnings-growth ratio of 1.65 and a beta of 0.94.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings results on Thursday, November 2nd. The medical equipment provider reported $0.24 earnings per share for the quarter, beating analysts’ consensus estimates of $0.20 by $0.04. Lantheus had a net margin of 9.59% and a negative return on equity of 46.45%. The firm had revenue of $79.94 million during the quarter, compared to the consensus estimate of $77.18 million. During the same period in the prior year, the firm earned $0.15 EPS. The business’s revenue was up 9.4% on a year-over-year basis. equities research analysts predict that Lantheus Holdings Inc will post 1.05 earnings per share for the current year.

WARNING: This piece was originally reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this piece on another domain, it was stolen and republished in violation of US & international trademark and copyright law. The legal version of this piece can be read at https://sportsperspectives.com/2017/12/11/macquarie-group-ltd-takes-position-in-lantheus-holdings-inc-lnth.html.

About Lantheus

Lantheus Holdings, Inc is engaged in the development, manufacture and commercialization of diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. Its imaging agents and products are used across a range of imaging modalities, including echocardiography and nuclear imaging.

Institutional Ownership by Quarter for Lantheus (NASDAQ:LNTH)

Receive News & Ratings for Lantheus Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus Holdings Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply